DSpace Repository

IMMray¿ PanCan-d test performance in detecting early stage pancreatic cancer in high risk symptomatic patients

Show simple item record

APA

Dierks, D & Zandian, A & King, T & Brand, R & Ney, A & Pereir, S & Moser, AJ & Perez Melar, G & Decicco, C & Carrato, A & Castillo, María Encarnación & Earl, J & Persson, J & Stein, H & Grützmann, R & Dexlin Mellby, L (2021-09 ) .IMMray¿ PanCan-d test performance in detecting early stage pancreatic cancer in high risk symptomatic patients.

ISO 690

Dierks, D & Zandian, A & King, T & Brand, R & Ney, A & Pereir, S & Moser, AJ & Perez Melar, G & Decicco, C & Carrato, A & Castillo, María Encarnación & Earl, J & Persson, J & Stein, H & Grützmann, R & Dexlin Mellby, L. 2021-09 .IMMray¿ PanCan-d test performance in detecting early stage pancreatic cancer in high risk symptomatic patients.

https://hdl.handle.net/20.500.12080/39591
dc.contributor.author Dierks, D
dc.contributor.author Zandian, A
dc.contributor.author King, T
dc.contributor.author Brand, R
dc.contributor.author Ney, A
dc.contributor.author Pereir, S
dc.contributor.author Moser, AJ
dc.contributor.author Perez Melar, G
dc.contributor.author Decicco, C
dc.contributor.author Carrato, A
dc.contributor.author Castillo, María Encarnación
dc.contributor.author Earl, J
dc.contributor.author Persson, J
dc.contributor.author Stein, H
dc.contributor.author Grützmann, R
dc.contributor.author Dexlin Mellby, L
dc.date.accessioned 2024-02-08T13:00:48Z
dc.date.available 2024-02-08T13:00:48Z
dc.date.created 2021-09
dc.date.issued 2021-09
dc.identifier.uri https://hdl.handle.net/20.500.12080/39591
dc.description.abstract The test performance of a blood based IMMray¿ PanCan-d biomarker signature together with CA 19-9 was recently evaluated in clinical retrospective study. The study was designed to evaluate detection of early stage (stage I&II) pancreatic ductal adenocarcinoma (PDAC) in high risk patients with non-specific but concerning symptoms for PDAC. In total, 433 patient serum samples, including 202 PDAC stage I-IV, 89 early stage PDAC stage I&II, and 231 early symptomatic controls were analyzed with IMMray¿ PanCan-d biomarker signature and CA 19-9 assay. All samples were freshly collected at seven reference sites in USA and Europe. The results showed that early stage PDAC I&II could be separated from symptomatic controls with specificity of 92% and sensitivity of 80%, and PDAC stage I-IV was differentiated with specificity of 92% and sensitivity of 81%. Detecting pancreatic cancer as early as possible in high risk symptomatic patients is a challenging but extremely important achievement that could support clinicians in providing accelerated and correct diagnosis to the patients. es_ES
dc.format application/pdf es_ES
dc.language eng es_ES
dc.rights CC-BY es_ES
dc.rights.uri http://creativecommons.org/licenses/by/4.0/deed.es es_ES
dc.title IMMray¿ PanCan-d test performance in detecting early stage pancreatic cancer in high risk symptomatic patients es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.rights.accessrights info:eu-repo/semantics/restrictedAccess es_ES
dc.identifier.location N/A es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

CC-BY Except where otherwise noted, this item's license is described as CC-BY

Search DSpace


Browse

My Account

Social Media